249 related articles for article (PubMed ID: 12086292)
1. Outcomes studies of the gastrointestinal safety of cyclooxygenase-2 inhibitors.
Scheiman JM
Cleve Clin J Med; 2002; 69 Suppl 1():SI40-6. PubMed ID: 12086292
[TBL] [Abstract][Full Text] [Related]
2. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study.
Silverstein FE; Faich G; Goldstein JL; Simon LS; Pincus T; Whelton A; Makuch R; Eisen G; Agrawal NM; Stenson WF; Burr AM; Zhao WW; Kent JD; Lefkowith JB; Verburg KM; Geis GS
JAMA; 2000 Sep; 284(10):1247-55. PubMed ID: 10979111
[TBL] [Abstract][Full Text] [Related]
3. New directions in symptomatic therapy for patients with osteoarthritis and rheumatoid arthritis.
Hochberg MC
Semin Arthritis Rheum; 2002 Dec; 32(3 Suppl 1):4-14. PubMed ID: 12528069
[TBL] [Abstract][Full Text] [Related]
4. An evidence-based evaluation of the gastrointestinal safety of coxibs.
Bombardier C
Am J Cardiol; 2002 Mar; 89(6A):3D-9D. PubMed ID: 11909555
[TBL] [Abstract][Full Text] [Related]
5. Gastroduodenal safety of cyclooxygenase-2 inhibitors.
Scheiman JM
Curr Pharm Des; 2003; 9(27):2197-206. PubMed ID: 14529400
[TBL] [Abstract][Full Text] [Related]
6. What have we learned from the large outcomes trials of COX-2 selective inhibitors? The rheumatologist's perspective.
Hochberg MC
Clin Exp Rheumatol; 2001; 19(6 Suppl 25):S15-22. PubMed ID: 11695246
[TBL] [Abstract][Full Text] [Related]
7. Current perspective on the cardiovascular effects of coxibs.
Konstam MA; Weir MR
Cleve Clin J Med; 2002; 69 Suppl 1():SI47-52. PubMed ID: 12086293
[TBL] [Abstract][Full Text] [Related]
8. Gastrointestinal safety and tolerability of nonselective nonsteroidal anti-inflammatory agents and cyclooxygenase-2-selective inhibitors.
Peura DA
Cleve Clin J Med; 2002; 69 Suppl 1():SI31-9. PubMed ID: 12086291
[TBL] [Abstract][Full Text] [Related]
9. Gastrointestinal safety of coxibs and outcomes studies: what's the verdict?
Laine L
J Pain Symptom Manage; 2002 Apr; 23(4 Suppl):S5-10; discussion S11-4. PubMed ID: 11992743
[TBL] [Abstract][Full Text] [Related]
10. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial.
Simon LS; Weaver AL; Graham DY; Kivitz AJ; Lipsky PE; Hubbard RC; Isakson PC; Verburg KM; Yu SS; Zhao WW; Geis GS
JAMA; 1999 Nov; 282(20):1921-8. PubMed ID: 10580457
[TBL] [Abstract][Full Text] [Related]
11. COX-2-specific inhibitors and the kidney: effect on hypertension and oedema.
Whelton A
J Hypertens Suppl; 2002 Sep; 20(6):S31-5. PubMed ID: 12683425
[TBL] [Abstract][Full Text] [Related]
12. The gastrointestinal effects of nonselective NSAIDs and COX-2-selective inhibitors.
Laine L
Semin Arthritis Rheum; 2002 Dec; 32(3 Suppl 1):25-32. PubMed ID: 12528071
[TBL] [Abstract][Full Text] [Related]
13. The cost-effectiveness of cyclooxygenase-2 selective inhibitors in the management of chronic arthritis.
Spiegel BM; Targownik L; Dulai GS; Gralnek IM
Ann Intern Med; 2003 May; 138(10):795-806. PubMed ID: 12755551
[TBL] [Abstract][Full Text] [Related]
14. Gastrointestinal safety of selective COX-2 inhibitors.
Hawkey CJ; Skelly MM
Curr Pharm Des; 2002; 8(12):1077-89. PubMed ID: 11945152
[TBL] [Abstract][Full Text] [Related]
15. Clinical pharmacology of selective COX-2 inhibitors.
Capone ML; Tacconelli S; Sciulli MG; Patrignani P
Int J Immunopathol Pharmacol; 2003; 16(2 Suppl):49-58. PubMed ID: 14552704
[TBL] [Abstract][Full Text] [Related]
16. The gastrointestinal safety of the COX-2 selective inhibitor etoricoxib assessed by both endoscopy and analysis of upper gastrointestinal events.
Hunt RH; Harper S; Watson DJ; Yu C; Quan H; Lee M; Evans JK; Oxenius B
Am J Gastroenterol; 2003 Aug; 98(8):1725-33. PubMed ID: 12907325
[TBL] [Abstract][Full Text] [Related]
17. Developing an economic rationale for the use of selective COX-2 inhibitors for patients at risk for NSAID gastropathy.
Fendrick AM
Cleve Clin J Med; 2002; 69 Suppl 1():SI59-64. PubMed ID: 12086296
[TBL] [Abstract][Full Text] [Related]
18. Gastrointestinal tolerability of the selective cyclooxygenase-2 (COX-2) inhibitor rofecoxib compared with nonselective COX-1 and COX-2 inhibitors in osteoarthritis.
Watson DJ; Harper SE; Zhao PL; Quan H; Bolognese JA; Simon TJ
Arch Intern Med; 2000 Oct; 160(19):2998-3003. PubMed ID: 11041909
[TBL] [Abstract][Full Text] [Related]
19. COX-2 inhibitors and the cardiovascular system.
FitzGerald GA; Cheng Y; Austin S
Clin Exp Rheumatol; 2001; 19(6 Suppl 25):S31-6. PubMed ID: 11695249
[TBL] [Abstract][Full Text] [Related]
20. Balancing gastroprotection and cardioprotection with selective cyclo-oxygenase-2 inhibitors: clinical implications.
Meagher EA
Drug Saf; 2003; 26(13):913-24. PubMed ID: 14583067
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]